Rxivist logo

Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19

By Xiangyu Chen, Zhiwei Pan, Shuai Yue, Fei Yu, Junsong Zhang, Yang Yang, Ren Li, Bingfeng Liu, Xiaofan Yang, Leiqiong Gao, Zhirong Li, Yao Lin, Qizhao Huang, Lifan Xu, Jianfang Tang, Li Hu, Jing Zhao, Pinghuang Liu, Guozhong Zhang, Yaokai Chen, Kai Deng, Lilin Ye

Posted 30 Jul 2020
medRxiv DOI: 10.1101/2020.07.29.20164285

COVID-19 patients exhibit differential disease severity after SARS-CoV-2 infection. It is currently unknown as to the correlation between the magnitude of neutralizing antibody (NAb) responses and the disease severity in COVID-19 patients. In a cohort of 59 recovered patients with disease severity including severe, moderate, mild and asymptomatic, we observed the positive correlation between serum neutralizing capacity and disease severity, in particular, the highest NAb capacity in sera from the patients with severe disease, while a lack of ability of asymptomatic patients to mount competent NAbs. Furthermore, the compositions of NAb subtypes were also different between recovered patients with severe symptoms and with mild-to-moderate symptoms. These results reveal the tremendous heterogeneity of SARS-CoV-2-specific NAb responses and their correlations to disease severity, highlighting the needs of future vaccination in COVID-19 patients recovered from asymptomatic or mild illness.

Download data

  • Downloaded 452 times
  • Download rankings, all-time:
    • Site-wide: 74,435
    • In infectious diseases: 3,877
  • Year to date:
    • Site-wide: 86,612
  • Since beginning of last month:
    • Site-wide: 101,250

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide